netFormulary The Pennine Acute Hospitals NHS
NHS Trust Formulary  
 Search
 Formulary Chapter 3: Respiratory system - Full Chapter
Chapter Links...
 Details...
03.04.02  Expand sub section  Allergen Immunotherapy
Bee and Wasp Allergen Extracts (Pharmalgen«)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary Subcutaneous injection

Restricted ItemáSpecialist Use Only 
Link  NICE TA246: Pharmalgen for the treatment of bee and wasp venom allergy
   
Benralizumab (Fasenra«)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
BlueTeq

Subcutaneous injection

 
Link  NICE TA565: Benralizumab for treating severe eosinophilic asthma
   
Mepolizumab (Nucala«)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
BlueTeq

Subcutaneous injection

 
Link  NICE TA431: Mepolizumab for treating severe refractory eosinophilic asthma
   
Reslizumab (Cinqaero«)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
NHS England
BlueTeq

IV infusion

 
Link  NICE TA479: Reslizumab for treating severe eosinophilic asthma
   
03.04.02  Expand sub section  Omalizumab
Omalizumab (Xolair«)
View adult BNF View SPC online View childrens BNF  Track Changes
Restricted Drug Restricted
Red
BlueTeq

Subcutaneous injection

 
Link  NICE TA278: Omalizumab for treating severe persistent allergic asthma
   
 ....
 Non Formulary Items
Grass and Tree Pollen Extract  (Pollinex®)

View adult BNF View SPC online View childrens BNF
Non Formulary
 
Grass pollen extract  (Grazax«)

View adult BNF View SPC online View childrens BNF Track Changes
Non Formulary
Black
Not recommended for the treatment of grass pollen induced hayfever in adult patients with clinically relevant symptoms and a positive skin-prick test or specific IgE test to grass pollen. It was not deemed to be cost effective and was a low priority for funding.
 
  
Key
note Notes
Section Title Section Title (top level)
Section Title Section Title (sub level)
First Choice Item First Choice item
Non Formulary Item Non Formulary section
Restricted Drug
Restricted Drug
Unlicensed Drug
Unlicensed
Track Changes
Display tracking information
click to search medicines.org.uk
Link to adult BNF
click to search medicines.org.uk
Link to children's BNF
click to search medicines.org.uk
Link to SPCs
SMC
Scottish Medicines Consortium
Cytotoxic Drug
Cytotoxic Drug
CD
Controlled Drug
High Cost Medicine
High Cost Medicine
Cancer Drugs Fund
Cancer Drugs Fund
NHSE
NHS England
Homecare
Homecare
CCG
CCG

Traffic Light Status Information

Status Description

Amber

Drugs designated amber are suitable for shared care arrangements under a shared care protocol. Prescribing may be transferred from secondary to primary care once the patient is stabilised and agreed shared care arrangements have been established. Alternatively primary care may initiate under the supervision of secondary care if this option is given in the shared care document. It is recommended that shared care arrangements should be drawn up following local discussion and agreement by prescribing parties.   

Black

These products have been reviewed by the GM Joint Formulary Group and have been deemed not suitable for prescribing for adults in primary or secondary care within Greater Manchester. These decisions have been made on the basis of safety, efficacy and cost-effectiveness of the products.  

Green

Not used   

Green 1

Drugs designated green1 are suitable for initiation and ongoing prescribing within primary care.   

Green 2

Drugs designated green2 can be initiated by primary care following written or verbal advice from a specialist and then be subsequently safely prescribed in primary care with little or no monitoring required.  

Green 3

Drugs designated green3 are suitable for on-going prescribing within primary care after specialist initiation and an initial review (unless specified) in secondary care. Little or no monitoring is required.  

Grey

Not suitable for routine prescribing but may be suitable for a defined patient population. Whilst prescribers should think very carefully before prescribing or recommending any of the products on the grey list, there may be exceptional instances when the use of one of these products is necessary for a particular patient.   

Red

Drugs designated red are considered to be specialist medicines and prescribing responsibility for these medicines should normally remain with the consultant or specialist clinician. These drugs should not be initiated or prescribed in primary care. It is recommended that the supply of these specialist medicines should be organised via the hospital pharmacy, this may include arranging for supply via a home care company.   

netFormulary